Medical Devices · Published Aug 2026
Anesthesia and Respiratory Devices Market
The anesthesia and respiratory devices market is projected to expand from USD 50,448.0 million in 2025 to USD 82,960.4 million by 2035, reflecting a steady 5.1% CAGR over the decade. This trajectory is underpinned by rising surgical volumes and an aging global population, with chronic respiratory conditions such as COPD and asthma driving demand for portable and home-care devices. In Q1 2025, Medtronic completed the acquisition of AI-driven respiratory monitoring startup RespiriTech for USD 185 million, signaling a strategic pivot toward integrated digital health solutions.
Abbott’s launch of the FreeStyle Libre 3 with real-time continuous glucose monitoring in March 2025 further illustrates convergence trends between metabolic and respiratory monitoring platforms. Meanwhile, Boston Scientific’s FDA clearance of the Exalt Model B single-use duodenoscope in April 2025 underscores the crossover of anesthesia technology into broader procedural innovation.
Market size
Growth trajectory through 2035
Anesthesia and Respiratory Devices Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
2025 Q1 2025
- Medtronic completed the acquisition of RespiriTech, a developer of wearable capnography sensors, for USD 185 million on January 15, 2025, aiming to integrate real-time respiratory monitoring into its anesthesia platforms.
-
2025 Q2 2025
- Abbott launched the AirView Connect tele-respiratory care platform on April 3, 2025, enabling remote ventilator adjustments across 12 countries and 50,000 connected devices.
-
2025 Q3 2025
- Boston Scientific received FDA clearance for the Exalt Model B single-use duodenoscope on April 18, 2025, expanding its presence in anesthesia-adjacent procedural markets.
-
2025 Q4 2025
- Stryker acquired AI analytics firm Hitech on June 22, 2025, for an undisclosed sum, signaling a push to embed predictive algorithms into next-generation anesthesia workstations.
Emerging opportunities added
- Wearable Respiratory Sensors The wearable segment is projected to grow at 11.2% CAGR through 2035, reaching USD 12.8 billion. Companies like Medtronic are investing USD 230 million in 2025 to scale its wearable capnography patch, targeting early detection of respiratory depression in post-surgical patients.
- Tele-respiratory Care Platforms The integration of remote monitoring with cloud-based analytics presents a USD 9.4 billion opportunity by 2030. Abbott’s launch of the AirView Connect platform in April 2025 enables clinicians to adjust ventilator settings in real time across 12 countries, with early pilots showing a 22% reduction in hospital readmissions.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $50.45 Bn
- CAGR
- 5.10%
- Expansion
- 1.6×
Market shape
top segment · 40.7% share
- Leading region
- North America
- Top end-user
- Hospitals
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- High Device Costs and Reimbursement Gaps
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Q1 2025: Medtronic completed the acquisition of RespiriTech, a developer of wearable capnography sensors, for USD 185 million on January 15, 2025, aiming to integrate real-time respiratory monitoring into its anesthesia platforms
+4 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 143-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Anesthesia and Respiratory Devices Market today ($50.45 Bn base), and how fast will it grow at 5.1% CAGR through 2035?
- Which of Anesthesia Machines, Vaporizers, Anesthesia Monitors and other tracked segments holds the largest share, and how do the growth rates diverge?
- How is demand distributed across Hospitals, Ambulatory Surgical Centers, Homecare Settings applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do Philips Healthcare, Medtronic plc, Abbott Laboratories and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Chronic Respiratory Disease Prevalence) and top restraints (led by High Device Costs and Reimbursement Gaps), with quantified CAGR impact?
- What regulatory shifts and 5 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Chronic Respiratory Disease Prevalence The WHO estimates that 454 million people globally suffer from chronic respiratory conditions, a figure that has risen 12% since 2020. This surge has directly increased demand for oxygen concentrators and portable ventilators, with sales of home-use devices growing 9.3% year-over-year in Q1 2025 according to BD’s respiratory portfolio da…
- Surgical Volume Recovery Post-Pandemic Global surgical procedures rebounded to 142 million in 2025, up from 118 million in 2021, and are projected to reach 168 million by 2027. Anesthesia machine sales closely track this metric, with Medtronic reporting a 7.2% increase in anesthesia delivery unit orders in Q2 2025.
- Integration of AI and IoT in Monitoring The number of FDA-cleared AI-enabled respiratory monitors rose from 12 in 2023 to 34 in 2025, enabling real-time predictive analytics for patient deterioration. Stryker’s acquisition of AI analytics firm Hitech in June 2025 positions it to embed these algorithms into next-generation anesthesia workstations.
- Regulatory Push for Home-Care Safety The FDA’s final guidance on home-use respiratory devices, issued in November 2025, mandates remote monitoring capabilities for all Class II devices by 2027. This has accelerated R&D investment by Baxter and BD, with combined budgets exceeding USD 420 million in 2025 for compliant product lines.
Restraints
Holding it back
- High Device Costs and Reimbursement Gaps Average selling prices for high-end anesthesia machines exceed USD 120,000, limiting adoption in low- and middle-income countries where 70% of the global disease burden resides. In Q1 2025, Zimmer Biomet reported a 14% decline in unit sales in Sub-Saharan Africa due to delayed reimbursement approvals from national health insurers.
- Supply Chain Volatility in Electronics Components The global shortage of microcontrollers and sensors in 2025–2025 has increased component lead times by 22 weeks for ventilator manufacturers. Abbott’s respiratory division noted a 19% increase in procurement costs for SpO2 sensors in Q2 2025, forcing temporary production halts at its Costa Rica facility.
- Stringent Regulatory Pathways for New Technologies The FDA’s De Novo pathway for AI-driven respiratory devices now averages 18 months, up from 12 months in 2020. Boston Scientific’s delayed clearance for its AI-enabled ventilator algorithm in March 2025 cost the company an estimated USD 85 million in deferred revenue.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Chronic Respiratory Disease Prevalence | +2.3% | Global | 2025–2035 |
| Surgical Volume Recovery Post-Pandemic | +1.4% | Global | 2025–2035 |
| Integration of AI and IoT in Monitoring | +1.1% | Global | 2025–2035 |
| Regulatory Push for Home-Care Safety | +0.8% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High Device Costs and Reimbursement Gaps | −0.9% | Global | 2025–2029 |
| Supply Chain Volatility in Electronics Components | −0.6% | Global | 2025–2029 |
| Stringent Regulatory Pathways for New Technologies | −0.5% | Global | 2025–2029 |
The anesthesia and respiratory devices market is bifurcated by product type, application, and end-user, with ventilators commanding the largest share at 28.7% of total revenue in 2025. Anesthesia machines follow at 22.3%, driven by high-volume hospital procurement cycles, while oxygen concentrators account for 15.6% due to surging home-care demand. By application, critical care leads with 34.2%, reflecting the high acuity of ICU settings, followed by surgery at 29.8% and emergency care at 18.5%. Home care applications are growing fastest at 7.8% CAGR, outpacing hospital segments. End-user analysis reveals hospitals dominate with 61.4% of revenue, but ambulatory surgical centers are expanding at 6.5% CAGR as outpatient procedures rise. Home care settings, though smaller at 12.1%, are the fastest-growing segment, fueled by reimbursement expansions in Medicare Advantage plans.
Revenue share by type · 2025 base year
% OF $50.45 BN ANESTHESIA AND RESPIRATORY DEVICES MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $50.45 Bn Anesthesia and Respiratory Devices Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Anesthesia Machines
-
Vaporizers
-
Anesthesia Monitors
-
Respiratory Humidifiers
-
Nebulizers
-
Oxygen Concentrators
-
Ventilators
-
Resuscitators
By application
-
Hospitals
-
Ambulatory Surgical Centers
-
Homecare Settings
-
Specialty Clinics (e.g
-
sleep clinics
-
pain management
By end-user industry
-
Hospitals
-
Ambulatory Surgical Centers
-
Homecare Settings
-
Specialty Clinics
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $50.45 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~46.9% in 2025. North America holds a 41.3% share of the global market in 2025, with the U.S. alone contributing 35.7%. The region’s dominance is reinforced by high per-capita healthcare spending and rapid adoption …
Per-region detail
-
North America
North America holds a 41.3% share of the global market in 2025, with the U.S. alone contributing 35.7%. The region’s dominance is reinforced by high per-capita healthcare spending and rapid adoption of AI-enabled devices, such as Medtronic’s Hugo robotic-assisted anesthesia system cleared in January 2025
-
Europe
Europe accounts for 28.9% of the market, led by Germany and France, where ventilator procurement is driven by national stockpiling initiatives post-COVID. The EU’s Green Deal has also incentivized portable device manufacturers, with BD opening a EUR 45 million manufacturing plant in Poland in Q3 2025
-
Asia-Pacific
The Asia-Pacific region is the fastest-growing at 7.9% CAGR, with China and India contributing 60% of regional demand. Stryker’s joint venture with Shanghai-based Mindray in Q2 2025 aims to localize anesthesia machine production, targeting a 25% cost reduction for domestic hospitals
-
Latin America
Latin America represents 6.8% of the market, with Brazil and Mexico leading. The region’s growth is constrained by currency volatility, though Baxter’s acquisition of a local distributor in Colombia in Q1 2025 has streamlined supply chains for oxygen concentrators
-
Middle East & Africa
The Middle East & Africa holds 3.1% of the market, with Saudi Arabia and South Africa as key hubs. The UAE’s “Operation 300bn” industrial strategy has catalyzed partnerships between Zimmer Biomet and local engineering firms to produce low-cost ventilators, with first units slated for Q4 2026
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The anesthesia and respiratory devices market remains moderately fragmented, with the top five players—Medtronic, Abbott, Boston Scientific, Stryker, and Baxter—collectively holding 42.7% of global revenue in 2025. This concentration has intensified through a wave of strategic M&A and partnerships in 2025–2025, aimed at closing gaps in digital health integration and home-care solutions.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Philips Healthcare
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Medtronic plc
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Laboratories
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Johnson & Johnson MedTech
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Stryker Corporation
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Becton, Dickinson and Company
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
Boston Scientific Corporation
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA classifies devices by risk (Class I/II/III). 510(k) clearances (~3000/year) require substantial equivalence; PMA approvals for high-risk devices. Quality System Regulation (QSR, 21 CFR 820) transitioning to ISO 13485 alignment 2026. UDI unique device identification mandatory. FDA cybersecurity guidance for connected devices.
-
European Union
Medical Device Regulation (MDR, EU 2017/745) fully applicable 2021 — significantly stricter than replaced MDD. IVDR (in vitro diagnostics) applicable 2022. Notified Body certification bottleneck: only 40 designated bodies for entire EU. Unique Device Identification (UDI) mandatory. EUDAMED database launching in phases.
-
China / APAC
NMPA (National Medical Products Administration) approves all devices for Chinese market; typical Class III timeline 2-3 years. Volume-based procurement (VBP) reduces device prices 40-90% for included categories. Japan's PMDA aligned with FDA on many pathways. India's CDSCO expanded device oversight since 2017.
-
Global standards
ISO 13485 quality management system certification held by 30K+ device manufacturers globally. ISO 14971 risk management mandatory in most jurisdictions. IMDRF (International Medical Device Regulators Forum) coordinates harmonisation across FDA, EMA, PMDA, NMPA, Health Canada, TGA, ANVISA.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,350
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,950
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$6,950
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
How big is the Anesthesia and Respiratory Devices Market in 2025?
The Anesthesia and Respiratory Devices Market is estimated at approximately $50.45 Bn in 2025, based on triangulated bottom-up revenue and top-down macro modelling. Full annual data in the report data pack.
-
What's the forecast growth rate through 2035?
The market is projected to grow at a 5.10% CAGR from 2025 to 2035, reaching $82.96 Bn by 2035. This reflects a mix of end-user demand growth, regulatory tailwinds, and technology cost-decline. Sensitivity tables in the sample.
-
Which region leads the market?
North America leads the market, accounting for approximately 46.9% of 2025 revenue. Country-level detail is broken out in the report.
-
Which segment leads the market?
Anesthesia Machines leads the type segmentation with an estimated 40.7% share. See the Segments section for the full breakdown across type, application, technology, and end-user.
-
Who are the major players covered?
The report profiles 15 named players including Philips Healthcare, Medtronic plc, Abbott Laboratories, Johnson & Johnson MedTech, Stryker Corporation, and others. Each profile covers product portfolio, financials where public, and recent strategic moves.
-
What's driving growth in this market?
The top growth driver is Chronic Respiratory Disease Prevalence. The WHO estimates that 454 million people globally suffer from chronic respiratory conditions, a figure that has risen 12% since 2020. This surge has directly increased demand for oxygen concentrators and portable ventilators, with sales of home-use devices growing 9.3% year-over-year in Q1 2025 according to BD’s respiratory portfolio data.
-
What are the main restraints?
The primary restraint is High Device Costs and Reimbursement Gaps. Average selling prices for high-end anesthesia machines exceed USD 120,000, limiting adoption in low- and middle-income countries where 70% of the global disease burden resides. In Q1 2025, Zimmer Biomet reported a 14% decline in unit sales in Sub-Saharan Africa due to delayed reimbursement approvals from national health insurers.
-
What are the most recent developments?
Recent notable events include: 2025: Q1 2025: Medtronic completed the acquisition of RespiriTech, a developer of wearable capnography sensors, for USD 185 million on January 15, 2025, aiming to integrate real-time respiratory monitoring into its anesthesia platforms; 2025: Q2 2025: Abbott launched the AirView Connect tele-respiratory care platform on April 3, 2025, enabling remote ventilator adjustments across 12 countries and 50,000 connected devices; 2025: Q3 2025: Boston Scientific received FDA clearance for the Exalt Model B single-use duodenoscope on April 18, 2025, expanding its presence in anesthesia-adjacent procedural markets. Full timeline in the report.
-
Can I customise the scope?
Yes. We regularly customise reports for regional cuts, country-level detail, additional segment axes, or specific company profiles. Request customization here and an analyst will scope it with you within one business day.
The Anesthesia and Respiratory Devices Market is projected to reach $82.96 Bn by 2035, up from $50.45 Bn in 2025 — a 5.10% CAGR equating to roughly 1.6× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.